ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $89 | $0 | $1 | $6 |
| % Growth | 297,063.3% | -97.7% | -76.1% | – |
| Cost of Goods Sold | $21 | $0 | $0 | $0 |
| Gross Profit | $69 | $0 | $1 | $5 |
| % Margin | 76.9% | 100% | 100% | 96.1% |
| R&D Expenses | $20 | $20 | $18 | $20 |
| G&A Expenses | $0 | $47 | $18 | $5 |
| SG&A Expenses | $0 | $47 | $18 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $52 | $0 | $0 | -$0 |
| Operating Expenses | $72 | $68 | $37 | $25 |
| Operating Income | -$3 | -$68 | -$36 | -$19 |
| % Margin | -3.5% | -225,066.7% | -2,698.8% | -353.3% |
| Other Income/Exp. Net | $11 | $13 | $1 | -$1 |
| Pre-Tax Income | $8 | -$54 | -$35 | -$20 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $8 | -$54 | -$35 | -$20 |
| % Margin | 9% | -181,216.7% | -2,635.4% | -367.7% |
| EPS | 0.083 | -0.57 | -0.87 | -0.7 |
| % Growth | 114.5% | 34.5% | -24.3% | – |
| EPS Diluted | 0.078 | -0.57 | -0.87 | -0.7 |
| Weighted Avg Shares Out | 97 | 95 | 40 | 29 |
| Weighted Avg Shares Out Dil | 102 | 95 | 40 | 29 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$67 | -$35 | -$19 |
| % Margin | -3.4% | -224,823.3% | -2,674.5% | -349.5% |